
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc. demonstrates a strong potential for market success driven by the impressive efficacy profile of its lead program, TARA-002, which shows 100% durability and an 80% salvage rate upon re-induction. Additionally, the positive outcomes from clinical trials surrounding its intravenous choline chloride therapy highlight significant improvements in liver health, further strengthening the company’s position in treating rare diseases. With a robust safety profile and evolving competitive landscape, Protara is well-positioned to achieve wide adoption and sustained growth in its therapeutic offerings.
Bears say
Protara Therapeutics Inc reported a significant net loss of $12.7 million, translating to a loss of $0.48 per share in the fourth quarter of 2024, which raises concerns about the company's financial stability. Despite promising early signals from its TARA-002 program, the company's stock is trading at a steep discount relative to competitors, indicating potential undervaluation issues that may stem from market skepticism regarding future performance. Additionally, the competitive landscape in the NMIBC market, along with safety concerns regarding choline levels in patients, presents challenges that could hinder Protara's ability to effectively advance its therapies and improve investor confidence.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares